Abstract-Increased peripheral conduit artery stiffness has been shown in patients with heart failure (HF) with preserved ejection fraction. However, it is unknown whether this phenomenon extends to the coronary vasculature. HF with preserved ejection fraction may be driven, in part, by coronary inflammation, and inhibition of the enzyme DPP-4 (dipeptidyl-peptidase 4) reduces inflammation and oxidative stress. The purpose of this study was to determine the effect of saxagliptin-a DPP-4 inhibitor-on coronary stiffness in aortic-banded mini swine. We hypothesized saxagliptin would prevent increased coronary artery stiffness in a translational swine model with cardiac features of HF with preserved ejection fraction by inhibiting perivascular adipose tissue inflammation. Yucatan mini swine were divided into 3 groups: control, aortic-banded untreated HF, and aortic-banded saxagliptin-treated HF. Ex vivo mechanical testing was performed on the left circumflex and right coronary arteries, and advanced glycation end product, NF-κB (nuclear factor-κB), and nitrotyrosine levels were measured. An increase in the coronary elastic modulus of HF animals was associated with increased vascular advanced glycation end products, NF-κB, and nitrotyrosine levels compared with control and prevented by saxagliptin treatment. Aortas from healthy mice were treated with media from swine perivascular adipose tissue culture to assess its role on vascular stiffening. Conditioned media from HF and saxagliptin-treated HF animals increased mouse aortic stiffness; however, only perivascular adipose tissue from the HF group showed increased advanced glycation end products and NF-κB levels. In conclusion, our data show increased coronary conduit vascular stiffness was prevented by saxagliptin and associated with decreased advanced glycation end products, NF-κB, and nitrotyrosine levels in a swine model with potential relevance to HF with preserved ejection fraction. (Hypertension. 2018;72:466-475.
L arge elastic artery stiffness is an independent predictor of future cardiovascular events, 1,2 which also precedes and promotes hypertension. 3, 4 Increased aortic stiffness and central pulse pressure are associated with incident heart failure (HF) or end-organ damage, 5 and stiffening of the large conduit arteries has been proposed as a contributing factor to HF [6] [7] [8] [9] although recent evidence has increased scrutiny of this idea. 10 Increased aortic stiffness and afterload can cause greater transmission of energy to the coronary arteries, potentially increasing pulsatility and promoting cardiac damage. An important mechanism by which arterial stiffening can occur includes alterations to the extracellular matrix (ECM), in particular, increased collagen deposition. 11 Arterial stiffening may be further promoted by increased advanced glycation end product (AGE) abundance, which can increase collagen cross-linking. 11, 12 Diseasemediated changes to regulatory biomarkers of the ECM, such as MMPs (matrix metalloproteinases), play a key role in this process often through the decreased turnover of ECM proteins.
Accumulation of ECM proteins can occur via decreased levels or increased inhibition of MMPs resulting in reduced ECM turnover, greater collagen deposition, and subsequent promotion of AGE accumulation.
Oxidative stress and inflammation are well-established mediators of ECM components and regulatory mechanisms 13 and initiate important signaling cascades related to arterial stiffness. 14, 15 Perivascular adipose tissue (PVAT) may be an important source of increased oxidative stress, inflammation, and cytokine secretion during this process. [16] [17] [18] Increased PVAT surrounding the aorta is related to cardiovascular disease-related events, 19 associated with increased aortic stiffness, 20 and promotes arterial stiffness in animal models of aging and hypercholesterolemia. 21, 22 Less is understood about the effects of chronic cardiac pressure overload and adipose tissue-mediated inflammation on coronary artery stiffness-the key conduit artery supplying the heart. Recent work has proposed the idea that HF with preserved ejection fraction (HFpEF) is a total body disease driven, in part, by coronary inflammation, 23 and coronary perivascular adipose is known to secrete increased levels of cytokines during pathology. 21, 24 However, the specific influence of coronary perivascular adipose on coronary arterial stiffness in a setting of HF is unknown.
Recently, pharmacological inhibition of the enzyme DPP-4 (dipeptidyl-peptidase 4), using drugs commonly known as gliptins, has been shown to reduce systemic inflammation and oxidative stress. 25, 26 Gliptins have been examined as a means to treat vascular and cardiac remodeling in HF given that some circulating cardioactive and vasoactive factors known to be involved in fibrotic remodeling, such as NPY (neuropeptide Y) and SDF-1 (stromal cell-derived factor 1)-α, are substrates for DPP-4. [25] [26] [27] [28] Indeed, saxagliptin has been shown to prevent vascular remodeling and the associated increase in oxidative stress in a rodent model of diabetes mellitus. 29 Thus, the purpose of this study was to determine the chronic effects of saxagliptina DPP-4 inhibitor-on coronary artery stiffness and pulsatility in aortic-banded (AB) miniature swine exhibiting key clinical characteristics of HFpEF, including preserved ejection fraction at rest, diastolic dysfunction, depressed contractile reserve, left ventricular (LV) fibrosis, and lung congestion. [30] [31] [32] [33] [34] [35] [36] We tested 2 hypotheses: (1) chronic pressure overload will increase coronary artery stiffness, pulsatility, extracellular remodeling, oxidative stress, inflammation, and cytokine secretion mediated, in part, by PVAT; and (2) saxagliptin will preserve normal coronary arterial structure and compliance by preventing increases in PVAT inflammation and cytokine secretion.
Methods

Aortic Banding and Saxagliptin Treatment
The animals in the present study are the same animals used in recently published work from our laboratory in the Journal of the American Heart Association. 34 Data supporting the findings of this study may be requested from the corresponding author and subject to legal approval from AstraZenca. LV hypertrophy/HF was induced by aortic banding for a period of 24 weeks using methods previously published by our laboratory [30] [31] [32] 35, 37 with modifications. 34 Before aortic banding, intact male Yucatan miniature swine (11-14 kg; 3 months old) were assigned into 3 groups: nonsham sedentary control (n=6), AB-untreated HF (n=7), and AB saxagliptin-treated HF (HF-SAX; n=8). A systolic trans-stenotic gradient of ≈50 mm Hg (50±1 and 48±2, for HF and HF-SAX, respectively; P=nonsignificant) was achieved while maintaining a distal peripheral vascular mean arterial pressure of ≈90 mm Hg (90±1 and 90±1, for HF and HF-SAX, respectively; P=nonsignificant) under anesthesia using phenylephrine (1-3 µg/kg per minute, IV) at a heart rate of 100 bpm (96±6 and 102±6, for HF and HF-SAX, respectively; P=nonsignificant). Treatment with saxagliptin (10.0 mg/kg per day, oral; AstraZeneca Diabetes Alliance, Wilmington, DE) or placebo began 1 week post-aortic banding and continued daily for 23 weeks. Pharmacokinetic studies performed to determine saxagliptin dosing were described previously. 34 Animals were fed a standard diet averaging 15 to 20 g/kg QD, and water was provided ad libitum. Dissection of vital tissues occurred at the time of death. All animal protocols were in accordance with the Principles for the Utilization and Care of Vertebrate Animals Used in Testing Research and Training and approved by the University of Missouri Animal Care and Use Committee.
Statistical Analysis
All data analysis was performed using SPSS, version 19.0, or SigmaStat, version 3.5. Group comparisons were made using 1-way ANOVA or repeated measures ANOVA as appropriate. Group differences revealed by ANOVA were found using Student-Newman-Keuls post hoc analysis. All data are means±SE, and significance is reported at the P<0.05 level.
Results
LV Remodeling and Function
A thorough investigation of myocardial remodeling and LV function was provided for the same animals used in the current study in recently published work from our laboratory in the Journal of the American Heart Association. 34 Here, we provide a brief summary of these results, which indicated treatment with saxagliptin resulted in beneficial therapeutic effects in a translational pressure overload model of HF with potential relevance to human HFpEF. Aortic banding caused symptoms of HF in the HF group, including increased lung weights, concentric hypertrophic remodeling at the gross and cellular level, increased LV fibrosis, and diastolic dysfunction (increased slope of the end diastolic pressure-volume relationship). Ejection fraction and stroke volume at rest were normal in HF compared with control animals. Preserved resting systolic function in the presence of clinical markers of HF is a hallmark feature of HFpEF. Saxagliptin decreased DPP-4 activity by ≈70% in the HF-SAX group, and treatment prevented detrimental myocardial fibrotic remodeling and alterations to LV structure and function at the organ and cellular level resulting in maintenance of normal integration of systole and diastole during the cardiac cycle.
Coronary Vascular Stiffness and ECM Remodeling
Vascular stiffness of combined right coronary and left circumflex artery samples is presented in Figure 1A . A significant increase in the elastic modulus of the right coronary and left circumflex arteries in HF compared with control animals was associated with a significant increase in total collagen levels (expressed as the percentage area of media stained; Figure 1B ), indicative of increased vascular fibrosis. Increased vascular stiffness of coronary conduit arteries in the HF group was accompanied by a parallel increase in the coronary pulsatility index ( Figure 1C ) relative to control. Chronic saxagliptin treatment prevented aortic banding-induced increases in the coronary vascular elastic modulus, medial collagen content, and pulsatility index. Representative histological coronary vascular sections from control, HF, and HF-SAX groups are shown in Figure 1D .
Increased coronary vascular fibrosis in the HF group was associated with increased coronary vascular AGEs (Figure 2A ), nitrotyrosine ( Figure 2B ), and NF-κB (nuclear factor-κB; Figure 2C ) levels compared with control animals. A parallel increase in RAGE (receptor of advanced glycation end products) levels was not observed in the HF group ( Figure 2D ). Increased AGE levels were not associated with increased circulating blood glucose levels because plasma glucose was normal and similar between all groups for the duration of the study ( Figure 3A ). Aortic banding also decreased coronary vascular mRNA levels of the ECM regulatory biomarker MMP-9 in the HF group ( Figure 3B ). Nitrotyrosine, AGEs, and NF-κB levels were similar to control animals in the HF-SAX group (Figure 2A through 2C ), as were MMP-9 mRNA levels ( Figure 3B ). Although improved regulation of blood glucose was not a factor in the therapeutic effect of saxagliptin, we observed circulating plasma SDF-1 levels were chronically decreased in the HF-SAX group compared with those in control and HF animals ( Figure 3C ). In total, these findings indicate saxagliptin prevented aortic banding-induced fibrotic remodeling, pathological adaptations to regulation of profibrosis pathways, and increased vascular stiffness in the coronary arteries.
Coronary PVAT Increases Vascular Stiffness
Mouse aortas, cleared of perivascular fat and connective tissue from the vessel's adventitial surface, were cultured for 72 hours in media conditioned with pericoronary adipose tissue samples dissected from the swine groups. The elastic modulus was increased in mouse aorta exposed to conditioned media from the HF group compared with control ( Figure 4A ), indicating aortic banding induces changes to coronary perivascular tissue resulting in greater aortic vascular stiffness. Coronary perivascular fat conditioned media from HF animals showed increased levels of the cytokines TNF-α (tumor necrosis factor-α; Figure 4B ) and IL (interleukin)-10 ( Figure 4C ), but not IL-1β ( Figure 4D ), relative to the control group. Saxagliptin did not prevent the changes in cytokine secretion observed in perivascular fat after aortic banding. Conditioned media using pericoronary adipose tissue from the HF-SAX group also increased the elastic modulus (ie, stiffness) of cultured mouse aortas along with a parallel increase in adipose release of TNF-α and IL-10 compared with control. Similar to the coronary vasculature, levels of AGEs ( Figure 5A ) and NF-κB ( Figure 5C ) were increased without significant changes in nitrotyrosine ( Figure 5B) or RAGE ( Figure 5D ) in coronary PVAT from HF animals compared with the control group. Interestingly, changes in the levels of AGEs and NF-κB in pericoronary fat were prevented in the HF-SAX group ( Figure 5A and 5C). Neither coronary PVAT SRA (scavenger receptor A) levels ( Figure S2 in the online-only Data Supplement) nor adipocyte morphology (Table S1) were influenced by aortic banding or the saxagliptin intervention.
Discussion
In this study, we examined the effects of saxagliptin on indices of coronary artery stiffness in a translational swine model of pressure overload-induced HF. The results of this study illustrate several novel findings: (1) chronic pressure overload promotes coronary artery stiffness, reflected by an increased pulsatility index and profibrotic ECM alterations, which was prevented with saxagliptin; (2) attenuation of increased coronary stiffness, pulsatility, and profibrotic ECM changes in the HF group by saxagliptin was associated with concomitant reductions in coronary inflammation and oxidative stress; and (3) pericoronary fat from AB animals promotes arterial stiffness, independent of saxagliptin treatment.
The most important outcome of the current study is that saxagliptin prevented increased coronary artery stiffness and collagen deposition in a large animal model of experimental HF. These findings complement recently published work from our group in these same animals that demonstrated saxaglitpin also prevented increased LV collagen deposition. 34 Although increased large elastic artery stiffness in peripheral vessels is a well-established and independent predictor of future cardiovascular events and is associated with end-organ damage, the idea that this concept may also extend to the coronary vasculature and ultimately the heart is less well understood. The combined coronary vascular data from this study considered together with the cardiac findings from our previous study in these animals provide some of the first evidence supporting this connection in conduit coronary vasculature and the heart and importantly demonstrate the therapeutic efficacy of saxagliptin in preventing these pathological adaptations.
One of the most interesting findings of this study was that we observed an increase in coronary vascular inflammation and fibrosis in the absence of common comorbidities frequently observed in HF, including obesity and diabetes mellitus. This distinction is important, given other work has shown increased coronary artery conduit stiffness in an Ossabaw swine model of metabolic syndrome. 38 The observed increases in conduit coronary vascular nitrotryosine, NF-κB, and AGEs in the HF group lend support to the theory originally proposed by Paulus and Tschope that coronary vascular inflammation is a key negative stimulus contributing to pathological LV remodeling in HFpEF. Given that elevated plasma glucose is a well-recognized factor contributing to AGEs formation, it is interesting to observe increased coronary vascular AGE levels in an experimental setting of normoglycemia. However, AGE accumulation has been previously observed in a normoglycemic state that was attributed to increased oxidiative stress. 39 Overall, our data suggest that the proposed contribution of coronary inflammation to developing HF can occur solely in response to pressure overload, and imply this well-recognized pathway outlining potential links between oxidative stress and vascular stiffness may occur independently of common comorbidities (ie, metabolic derangement) often associated with HF in an experimental setting of cardiovascular disease.
From a mechanistic perspective, our data suggest coronary PVAT may be a significant source of cytokines potentially involved in the inflammatory process. PVAT may contribute to cardiovascular disease-related events, 19 contributes to aortic stiffness with aging and hypercholesterolemia, 20, 21, 40 and is an important source of oxidative stress, inflammation, and cytokine secretion shown to promote arterial stiffness and ECM alterations. 21, 22 To our knowledge, this is the first investigation to show coronary perivascular fat promotes arterial stiffness in a large animal model of pressure overload HF-absent metabolic disease. A strength of our experimental paradigm was the use of both swine and mouse animal models to examine the role of pericoronary adipose tissue as a mediator of vascular stiffness, and our results indicated media conditioned by swine PVAT from the HF group increased vascular stiffness in isolated mouse aortas. The conditioned media contained increased levels of both TNF-α and IL-10, but not IL-1β, implicating pericoronary adipose tissue as a potentially important contributor to the inflammatory process. Each of these cytokines have shown the potential to modulate arterial stiffness, [41] [42] [43] [44] [45] although it was previously unknown whether pressure overload would alter secretion of coronary PVAT TNF-α, IL-10, or IL-1β in a large animal model of HF. It is also important to note that increased IL-10 secretion from pericoronary fat could also contribute to arterial stiffness by promoting collagen deposition within the artery. 41, 46 NF-κB and AGE levels were also increased in swine coronary PVAT from HF animals, consistent with our observations in the coronary vasculature. Unlike the coronary arteries, oxidative stress assessed by nitrotyrosine abundance was not increased in the coronary PVAT of HF animals. NF-kB is a key mechanism promoting oxidative stress, which was increased relatively more in the coronary vasculature compared with PVAT (73% versus 17%, respectively). Thus, it is possible the magnitude of the NF-kB inflammatory stimulus was not great enough to promote a similar oxidative stress response in the pericoronary fat when compared with the vasculature. Alternatively, nitrotyrosine is dependent on NO and superoxide forming peroxynitrite that in turn modifies tyrosine residues. It is possible that NO levels within the components of the blood vessel (endothelium, smooth muscle, and adventitia) differ from those observed in the the pericoronary fat samples. These findings suggest other mechanisms of oxidative stress may play a role in the differences observed in the current study between the coronary vessels and adipose tissue.
Alterations to the ECM, particularly increased collagen deposition (which also contributes to AGEs [advanced glycation end products] accumulation), is another significant mechanism that promotes arterial stiffness, which is mediated by oxidative stress and inflammation. 13 Thus, the increased coronary vascular collagen and AGE levels in the current study may also be due, in part, to reduced collagen turnover allowing for greater accumulation of these specific ECM components. Our data support this idea because mRNA levels of an important regulatory biomarker of the ECM, MMP-9, were reduced in the coronary arteries of the HF group. Further, we previously reported increased levels of plasma NPY-a known DPP-4 substrate-were positively correlated with LV fibrosis in these same animals. 34 Together, these findings implicate potential mechanisms by which coronary PVAT locally enhances inflammation, cytokine secretion, and subsequent oxidative stress, which may work in parallel with circulating systemic factors and regulatory mechanisms of the ECM to promote fibrotic remodeling of the vasculature and possibly also the ventricle.
34
Perspectives
Our findings suggest saxagliptin could hold therapeutic potential for reducing vascular stiffness. Human studies have shown increased peripheral conduit artery stiffness in patients with HFpEF, [6] [7] [8] 47, 48 and we have reported increased carotid artery stiffness in this same swine pressure overload-induced model of HF. 35, 49 The outcomes of the current study suggest increased conduit coronary artery stiffening may also be part of this process. Our data indicate the therapeutic benefits of saxagliptin may be realized via general prevention of inflammation and oxidative stress. DPP-4 inhibition has previously been shown in clinical trials to decrease nitrotyrosine, NF-κB kinase, and IL-6 in patients with type 2 diabetes mellitus, 26, 50, 51 and results from the current study parallel these findings nicely. From a systemic perspective, our observation that saxagliptin chronically decreased plasma levels of SDF-1 and prevented increased NPY as reported previously in the HF group 34 is more difficult to reconcile. Although it would be logical to predict increases in both SDF-1 and NPY after chronic systemic DPP-4 inhibition by saxagliptin, the long-term impact of enzymatic inhibition on these DPP-4 substrates is still largely unknown. In particular, SDF-1 signaling through the CXCR4 chemokine receptor can be difficult to interpret given its ability to attract both circulating mesenchymal stromal cells and fibrocytes, illustrating how fine tuning of this chemokine could result in either profibrotic or antifibrotic inflammatory processes. 52 Saxagliptin also preserved normal coronary mRNA levels of MMP-9, implicating this important ECM regulatory biomarker as another potential target of its beneficial actions.
We would be remiss to ignore the finding that media conditioned with adipose tissue from HF-SAX-treated animals also increased aortic stiffness in isolated mouse aortas and contained similarly elevated levels of both TNF-α and IL-10 as observed in the HF group. We have previously shown that treatment with the antioxidant TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl) reverses age-related aortic collagen deposition but not aortic AGE accumulation, 14 suggesting an interaction between oxidative stress and inflammation is important to the overall pathological response. In this regard, part of the effectiveness of saxaglitpin in the current study may be explained by its positive therapeutic action on both inflammatory and oxidative stress markers, potentially interrupting this interaction while preserving normal structural and regulatory components of the ECM. Thus, we think it is reasonable to speculate the effects of saxagliptin prevented increases in conduit coronary arterial stiffness in the HF-SAX group, despite the finding that pericoronary adipose conditioned media from HF-SAX animals contained increased cytokines.
Although a potential limitation of the vessel culture in adipose conditioned media approach is the phenotypic differences between pig coronary arteries and mouse aorta, this ex vivo model is the first to elucidate the potential role of coronary PVAT to promote arterial stiffness in a large animal model of pressure overload-induced heart failure. Previous studies have demonstrated perivascular adipose-derived TNF-α promotes vascular inflammation in small arteries from obese patients. 18 Consistent with this finding, pericoronary adipose tissue-mediated arterial stiffness and TNF-α secretion were increased in both AB groups irrespective of treatment. Although our results clearly indicate PVAT contributes to coronary arterial stiffening in this experimental HF model, prevention of these inflammatory processes in the fat depot itself does not seem to be requisite for the therapeutic effects of saxagliptin to be realized. Future studies examining coronary stiffness by culturing the artery in either the presence or absence of the adjacent fat in combination with specific cytokine inhibitors of TNF-α or IL-10 may prove helpful in elducidating their mechanistic role in this process. 21, 22 Finally, we cannot exclude the possibility phenotypic differences between the coronary and aorta may have had on our results. The initial findings presented herein provide the basis for future investigations using isolated coronary vessels from healthy untreated pigs to help elucidate whether the increased stiffness observed in mouse aortas after exposure to swine PVAT is still observed in the relevant vascular bed.
In summary, we provide novel evidence for saxagliptin to preserve normal coronary arterial stiffness and prevent pathological fibrotic remodeling in a translational pressure overload-induced model of HF. The effects of saxagliptin were realized in the absence of chronically elevated blood glucose levels, demonstrating the drug may have positive value in a clinical setting of hypertension in the absence of metabolic disease. Collectively, our data provide insight on the therapeutic potential of saxagliptin to prevent increased coronary conduit vascular stiffness in a large animal model with potential relevance to HFpEF and suggest this benefit may occur by prevention of both systemic and local oxidative stress and inflammation. Additional studies will be necessary to demonstrate the importance of coronary artery stiffening to clinical outcomes to establish the human significance of these findings and determine whether they relate to cardiovascular events similarly to increases in carotid or aortic stiffness as established previously.
